当前位置: 首页 >> 检索结果
761. A phase I trial of intranasal Moli1901 for cystic fibrosis.
The peptide drug Moli1901 activates an alternative chloride channel that is present in cystic fibrosis (CF) nasal and airway epithelia. Doing so bypasses the dysfunctional CF transmembrane regulator.
762. Lack of efficacy for a cervicomandibular support collar in the management of obstructive sleep apnea.
作者: Margot A Skinner.;Ruth N Kingshott.;David R Jones.;D Robin Taylor.
来源: Chest. 2004年125卷1期118-26页
The effect of therapy using a cervicomandibular support collar (CMSC) to manage obstructive sleep apnea (OSA) was compared with standard therapy, nasal continuous positive airway pressure (nCPAP).
763. Effect of three wound dressings on infection, healing comfort, and cost in patients with sternotomy wounds: a randomized trial.
作者: Rochelle Wynne.;Mari Botti.;Hilary Stedman.;Lynda Holsworth.;Maria Harinos.;Olivia Flavell.;Christianne Manterfield.
来源: Chest. 2004年125卷1期43-9页
To compare three dressing types in terms of their ability to protect against infection and promote healing, patient comfort, and cost-effectiveness.
764. Adaptation of pulmonary oxygen consumption slow component following 6 weeks of exercise training above and below the lactate threshold in untrained men.
作者: Jeffrey V Ocel.;Larry E Miller.;Lee M Pierson.;David F Wootten.;Brian J Hawkins.;Jonathan Myers.;William G Herbert.
来源: Chest. 2003年124卷6期2377-83页
To examine the effects of 6 weeks of exercise training above or below the lactate threshold (LT) on the slow component (SC) of pulmonary oxygen consumption (.VO(2)).
765. Effect of guaifenesin on cough reflex sensitivity.
Guaifenesin, a commonly used agent for the treatment of cough, is termed an expectorant since it is believed to alleviate cough discomfort by increasing sputum volume and decreasing its viscosity, thereby promoting effective cough. Despite its common usage, relatively few studies, yielding contrasting results, have been performed to investigate the action and efficacy of guaifenesin.
766. Initial experience on rifampin and pyrazinamide vs isoniazid in the treatment of latent tuberculosis infection among patients with silicosis in Hong Kong.
作者: Chi Chiu Leung.;Wing Sze Law.;Kwok Chiu Chang.;Cheuk Ming Tam.;Wing Wai Yew.;Chi Kuen Chan.;Man Yee Wong.
来源: Chest. 2003年124卷6期2112-8页
To compare the adverse effects and treatment adherence between 2 months of rifampin plus pyrazinamide (2RZ) and 6 months of isoniazid (6H).
767. Improvement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumes.
In patients with COPD, changes in inspiratory capacity (IC) have shown a higher correlation to patient-focused outcomes, such as dyspnea with exercise, than other standard spirometric measurements. Changes in IC reflect changes in hyperinflation. Tiotropium is a once-daily inhaled anticholinergic that has its effect through prolonged M3 muscarinic receptor antagonism and has demonstrated sustained improvements in spirometric and health outcomes. We sought to evaluate changes in resting IC and lung volumes after long-term administration of tiotropium.
768. A role for anabolic steroids in the rehabilitation of patients with COPD? A double-blind, placebo-controlled, randomized trial.
作者: Eva C Creutzberg.;Emiel F M Wouters.;Rob Mostert.;Rob J Pluymers.;Annemie M W J Schols.
来源: Chest. 2003年124卷5期1733-42页
Skeletal muscle weakness commonly occurs in patients with COPD. Long-term use of systemic glucocorticosteroids further contributes to muscle weakness. Anabolic steroids could be an additional mode of intervention to improve outcome of pulmonary rehabilitation by increasing physiologic functioning, possibly mediated by increasing erythropoietic function.
769. All-trans retinoic acid modulates the balance of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in patients with emphysema.
作者: Jenny T Mao.;Donald P Tashkin.;Paula N Belloni.;Irene Baileyhealy.;Felicita Baratelli.;Michael D Roth.
来源: Chest. 2003年124卷5期1724-32页
The balance between proteases and antiproteases plays an essential role in the pathogenesis of emphysema. This study was designed to evaluate the impact of all-trans retinoic acid (ATRA) on the balance of matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of metalloproteinase-1 (TIMP-1) in patients with emphysema.
770. Safety of nitrate withdrawal in angina-free and hemodynamically stable patients with coronary artery disease.
作者: Jacob George.;Ilan Kitzis.;David Zandorf.;Michal Golovner.;Itzhak Shapira.;Shlomo Laniado.;Arie Roth.
来源: Chest. 2003年124卷5期1652-7页
To assess the consequences of nitrate withdrawal in angina-free and hemodynamically stable coronary patients.
771. Inhaled fluticasone propionate by diskus in the treatment of asthma: a comparison of the efficacy of the same nominal dose given either once or twice a day.
In September 2000, the US Food and Drug Administration (FDA) approved the use of Flovent Diskus (FD) [fluticasone propionate; GlaxoSmithKline; Research Triangle Park, NC], which is an orally inhaled, dry-powder corticosteroid, for the maintenance treatment of asthma at dosages of 50 to 1,000 microg administered twice-daily. Once-daily dosage regimens did not receive approval. This article will detail six clinical trials, five of which incorporated comparative once-daily and twice-daily treatment arms of the same nominal dose of FD.
772. Reduction in ventilatory response to CO2 with relaxation feedback during CO2 rebreathing for ventilator patients.
Previous studies have shown that relaxation biofeedback reduced the amount of time spent receiving ventilation for difficult-to-wean patients.
773. Comparison of specific expiratory, inspiratory, and combined muscle training programs in COPD.
作者: Paltiel Weiner.;Rasmi Magadle.;Marinella Beckerman.;Margalit Weiner.;Noa Berar-Yanay.
来源: Chest. 2003年124卷4期1357-64页
Respiratory muscle weakness may contribute to dyspnea and exercise limitation in patients with significant COPD. In an attempt to reduce the severity of breathlessness and to improve exercise tolerance, inspiratory muscle training has been applied in many COPD patients. On the other hand, there is a paucity of data related to expiratory muscle performance and training in COPD.
774. Withdrawal from treatment as an outcome in the ISOLDE study of COPD.
作者: Peter M A Calverley.;Sally Spencer.;Lisa Willits.;P Sherwood Burge.;Paul W Jones.; .
来源: Chest. 2003年124卷4期1350-6页
To investigate the determinants of patient withdrawal from our study, and the effect of these withdrawals on the outcome of treatment with inhaled corticosteroids in patients with COPD.
775. Effect of montelukast on exhaled nitric oxide and nonvolatile markers of inflammation in mild asthma.
作者: Alessandra Sandrini.;Ivone M Ferreira.;Carlos Gutierrez.;Jose R Jardim.;Noe Zamel.;Kenneth R Chapman.
来源: Chest. 2003年124卷4期1334-40页
Leukotriene receptor antagonists appear to exert anti-inflammatory activity in asthma. We undertook the present study to evaluate the effect of montelukast on levels of exhaled nitric oxide (ENO) and two inflammatory markers, hydrogen peroxide (H(2)O(2)), and cysteinyl leukotrienes (cys-LTs), in the exhaled breath condensate of subjects with mild asthma.
776. Effects of short-term 28% and 100% oxygen on PaCO2 and peak expiratory flow rate in acute asthma: a randomized trial.
作者: Gustavo J Rodrigo.;Mario Rodriquez Verde.;Virginia Peregalli.;Carlos Rodrigo.
来源: Chest. 2003年124卷4期1312-7页
We conducted the first randomized controlled study to assess the effects of short-term 28% and 100% oxygen on PaCO(2) and peak expiratory flow rate (PEFR) in patients with acute severe asthma.
777. Pharmacodynamics and pharmacokinetics of inhaled iloprost, aerosolized by three different devices, in severe pulmonary hypertension.
作者: Horst Olschewski.;Beate Rohde.;Jürgen Behr.;Ralph Ewert.;Tobias Gessler.;H Ardeschir Ghofrani.;Thomas Schmehl.
来源: Chest. 2003年124卷4期1294-304页
Inhalation of iloprost, a stable prostacyclin analog, is an effective therapy for pulmonary hypertension with few side effects. This approach may, however, be handicapped by limitations of currently available nebulization devices. We assessed whether the physical characterization of a device is sufficient to predict drug deposition and pharmacologic effects.
778. Early mobilization of patients hospitalized with community-acquired pneumonia.
作者: Linda M Mundy.;Terry L Leet.;Kate Darst.;Mark A Schnitzler.;William Claiborne Dunagan.
来源: Chest. 2003年124卷3期883-9页
To determine if early mobilization (EM) of hospitalized adults with community-acquired pneumonia (CAP) reduces hospital length of stay.
779. An evaluation of nebulized levalbuterol in stable COPD.
作者: Debapriya Datta.;Anthony Vitale.;Bimalin Lahiri.;Richard ZuWallack.
来源: Chest. 2003年124卷3期844-9页
Levalbuterol, the R-isomer of albuterol, has advantages over racemic albuterol in asthma; however, the effectiveness of this beta-agonist in COPD has received little attention.
780. The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD.
作者: Nicola A Hanania.;Patrick Darken.;Donald Horstman.;Colin Reisner.;Benjamin Lee.;Suzanne Davis.;Tushar Shah.
来源: Chest. 2003年124卷3期834-43页
To compare the efficacy and safety of the inhaled corticosteroid fluticasone propionate (FP) and the inhaled long-acting beta(2)-agonist salmeterol (SM), when administered together in a single device (Diskus; GlaxoSmithKline, Inc; Research Triangle Park, NC), with that of placebo and the individual agents alone in patients with COPD.
|